Characteristics of patients
| Characteristic . | Value* . |
|---|---|
| Male sex | 159 (56) |
| Dates | |
| Myeloma diagnosis | December 1998–November 2008 |
| SCT | May 2000–February 2009 |
| Median age (10-90th percentile), y | 59 (45-68) |
| Serum M-protein | |
| Aκ | 38 (13) |
| Aλ | 14 (5) |
| Gκ | 103 (36) |
| Gλ | 70 (24) |
| Free κ | 18 (6) |
| Free λ | 19 (7) |
| M | 3 (1) |
| D | 2 (1) |
| Biclonal | 2 (1) |
| None | 17 (6) |
| Urine | |
| κ | 147 (51) |
| λ | 93 (33) |
| Anuric | 2 (1) |
| None | 44 (15) |
| Abnormal cytogenetics at SCT, n = 284 | 39 (14) |
| Myeloma bone disease apparent on plain radiographs, yes/no | 247 (86)/39 (14) |
| Prior radiation therapy, yes/no | 77 (27)/209 (73) |
| Median creatinine (10-90th percentile), μM | 79 (70-123) |
| Conditioning | |
| MEL200 | 246 (86) |
| MEL<200 | 23 (8) |
| MEL + Y90 anti-CD20 | 5 (2) |
| Samarium + MEL200 | 12 (4) |
| Median period from diagnosis to SCT (10-90th percentile), mo | 6.3 (4.5-10.8) |
| Stem cell mobilization, chemotherapy, and growth factor/growth factor only | 83 (29)/203 (71) |
| Disease status at SCT | |
| Plateau | 232 (81) |
| Never achieved PR (refractory) | 29 (10) |
| Relapse on therapy | 25 (9) |
| Median β2-microglobulin at initial diagnosis (10-90th percentile), mg/L, n = 208 | 3.40 (1.83-9.70) |
| Median labeling index (10-90th percentile), n = 282 | 0.2 (0-2.0) |
| Induction therapy administered, N = 324 | |
| Thalidomide dexamethasone | 189 (66) |
| Lenalidomide dexamethasone | 97 (34) |
| Characteristic . | Value* . |
|---|---|
| Male sex | 159 (56) |
| Dates | |
| Myeloma diagnosis | December 1998–November 2008 |
| SCT | May 2000–February 2009 |
| Median age (10-90th percentile), y | 59 (45-68) |
| Serum M-protein | |
| Aκ | 38 (13) |
| Aλ | 14 (5) |
| Gκ | 103 (36) |
| Gλ | 70 (24) |
| Free κ | 18 (6) |
| Free λ | 19 (7) |
| M | 3 (1) |
| D | 2 (1) |
| Biclonal | 2 (1) |
| None | 17 (6) |
| Urine | |
| κ | 147 (51) |
| λ | 93 (33) |
| Anuric | 2 (1) |
| None | 44 (15) |
| Abnormal cytogenetics at SCT, n = 284 | 39 (14) |
| Myeloma bone disease apparent on plain radiographs, yes/no | 247 (86)/39 (14) |
| Prior radiation therapy, yes/no | 77 (27)/209 (73) |
| Median creatinine (10-90th percentile), μM | 79 (70-123) |
| Conditioning | |
| MEL200 | 246 (86) |
| MEL<200 | 23 (8) |
| MEL + Y90 anti-CD20 | 5 (2) |
| Samarium + MEL200 | 12 (4) |
| Median period from diagnosis to SCT (10-90th percentile), mo | 6.3 (4.5-10.8) |
| Stem cell mobilization, chemotherapy, and growth factor/growth factor only | 83 (29)/203 (71) |
| Disease status at SCT | |
| Plateau | 232 (81) |
| Never achieved PR (refractory) | 29 (10) |
| Relapse on therapy | 25 (9) |
| Median β2-microglobulin at initial diagnosis (10-90th percentile), mg/L, n = 208 | 3.40 (1.83-9.70) |
| Median labeling index (10-90th percentile), n = 282 | 0.2 (0-2.0) |
| Induction therapy administered, N = 324 | |
| Thalidomide dexamethasone | 189 (66) |
| Lenalidomide dexamethasone | 97 (34) |
N = 286.
SCT indicates stem cell transplantation; MEL, melphalan; MEL200, high-dose melphalan (200 mg/m2); MEL<200, low-dose melphalan (< 200 mg/m2); and PR, partial response.
Categoric data are expressed as number and percentage of patients.